BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 33946592)

  • 1. Genetics of Familial Non-Medullary Thyroid Carcinoma (FNMTC).
    Diquigiovanni C; Bonora E
    Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33946592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The FOXE1 locus is a major genetic determinant for familial nonmedullary thyroid carcinoma.
    Bonora E; Rizzato C; Diquigiovanni C; Oudot-Mellakh T; Campa D; Vargiolu M; Guedj M; ; McKay JD; Romeo G; Canzian F; Lesueur F
    Int J Cancer; 2014 May; 134(9):2098-107. PubMed ID: 24127282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allelic loss of susceptibility loci and the occurrence of BRAF and RAS mutations in patients with familial non-medullary thyroid cancer.
    Na KY; Kim RM; Song EM; Lee JH; Lee J; Soh EY
    J Surg Oncol; 2012 Jan; 105(1):10-4. PubMed ID: 21826673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole exome and target sequencing identifies MAP2K5 as novel susceptibility gene for familial non-medullary thyroid carcinoma.
    Ye F; Gao H; Xiao L; Zuo Z; Liu Y; Zhao Q; Chen H; Feng W; Fu B; Sun L; Jiang X; He D; Jiang H; Yang M; Li L; Chen F; Liu X; Li S; Li Z; Jiang Y; Cheng L; Bu H
    Int J Cancer; 2019 Mar; 144(6):1321-1330. PubMed ID: 30132833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity.
    Capezzone M; Marchisotta S; Cantara S; Busonero G; Brilli L; Pazaitou-Panayiotou K; Carli AF; Caruso G; Toti P; Capitani S; Pammolli A; Pacini F
    Endocr Relat Cancer; 2008 Dec; 15(4):1075-81. PubMed ID: 18832444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Next generation sequencing technology for susceptible gene screening in familial non-medullary thyroid carcinoma].
    Dong L; Yu Y; Yu JP; Hao WJ; Zheng XQ; Cheng YN; Han L; Zhao JZ; Gao M
    Zhonghua Zhong Liu Za Zhi; 2017 Jan; 39(1):24-28. PubMed ID: 28104029
    [No Abstract]   [Full Text] [Related]  

  • 7. Familial nonmedullary thyroid carcinoma.
    Mazeh H; Sippel RS
    Thyroid; 2013 Sep; 23(9):1049-56. PubMed ID: 23734600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial non-medullary thyroid carcinoma: clinico-pathological features, current knowledge and novelty regarding genetic risk factors.
    Cirello V
    Minerva Endocrinol (Torino); 2021 Mar; 46(1):5-20. PubMed ID: 33045820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The long-term outcomes of the second generation of familial nonmedullary thyroid carcinoma are more aggressive than sporadic cases.
    Park YJ; Ahn HY; Choi HS; Kim KW; Park DJ; Cho BY
    Thyroid; 2012 Apr; 22(4):356-62. PubMed ID: 22280228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CHEK2 germline variants identified in familial nonmedullary thyroid cancer lead to impaired protein structure and function.
    Pires C; Marques IJ; Valério M; Saramago A; Santo PE; Santos S; Silva M; Moura MM; Matos J; Pereira T; Cabrera R; Lousa D; Leite V; Bandeiras TM; Vicente JB; Cavaco BM
    J Biol Chem; 2024 Mar; 300(3):105767. PubMed ID: 38367672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic susceptibility to hereditary non-medullary thyroid cancer.
    Kamani T; Charkhchi P; Zahedi A; Akbari MR
    Hered Cancer Clin Pract; 2022 Mar; 20(1):9. PubMed ID: 35255942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for interaction between the TCO and NMTC1 loci in familial non-medullary thyroid cancer.
    McKay JD; Thompson D; Lesueur F; Stankov K; Pastore A; Watfah C; Strolz S; Riccabona G; Moncayo R; Romeo G; Goldgar DE
    J Med Genet; 2004 Jun; 41(6):407-12. PubMed ID: 15173224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and Management of Hereditary Thyroid Cancer.
    Bano G; Hodgson S
    Recent Results Cancer Res; 2016; 205():29-44. PubMed ID: 27075347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of family history on non-medullary thyroid cancer.
    Nixon IJ; Suárez C; Simo R; Sanabria A; Angelos P; Rinaldo A; Rodrigo JP; Kowalski LP; Hartl DM; Hinni ML; Shah JP; Ferlito A
    Eur J Surg Oncol; 2016 Oct; 42(10):1455-63. PubMed ID: 27561845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial non-medullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations.
    Cavaco BM; Batista PF; Martins C; Banito A; do Rosário F; Limbert E; Sobrinho LG; Leite V
    Endocr Relat Cancer; 2008 Mar; 15(1):207-15. PubMed ID: 18310288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Familial nonmedullary thyroid cancer: a review of the genetics.
    Khan A; Smellie J; Nutting C; Harrington K; Newbold K
    Thyroid; 2010 Jul; 20(7):795-801. PubMed ID: 20465534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FAMILIAL NON-MEDULLARY THYROID CARCINOMA.
    Guda BB; Komisarenko II; Ostafiichuk MV; Tronko MD
    Exp Oncol; 2023 Jun; 45(1):70-78. PubMed ID: 37417280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a novel germline FOXE1 variant in patients with familial non-medullary thyroid carcinoma (FNMTC).
    Pereira JS; da Silva JG; Tomaz RA; Pinto AE; Bugalho MJ; Leite V; Cavaco BM
    Endocrine; 2015 May; 49(1):204-14. PubMed ID: 25381600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on familial nonmedullary thyroid cancer.
    Ammar SA; Alobuia WM; Kebebew E
    Endocrine; 2020 Jun; 68(3):502-507. PubMed ID: 32162184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic Mutations and Variants in the Susceptibility of Familial Non-Medullary Thyroid Cancer.
    Miasaki FY; Fuziwara CS; Carvalho GA; Kimura ET
    Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33218058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.